Clinical trials: Pulmonary Function Tests
ALS
Remote Pulmonary Function Testing and Nurse Coaching in ALS
Comparison of respiratory outcomes in patients receiving telemedicine-guided remote pulmonary function testing (rPFT) with or without the additional support of nurse coaching.
- Trial name
- NCT04490148
- Testing
- remote pulmonary function testing, standard pulmonary function testing, Nurse Respiratory Health Coaching (NRHC)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Milton S. Hershey Medical Center
Chronic Obstructive Pulmonary Disease (COPD)
A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
- Trial name
- NCT00363896
- Testing
- Aclidinium bromide
- Where
- 132 sites in Andorra, Austria and 14 more
- Volunteers
- 843 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Umeclidinium/vilanterol (UMEC/VI) is a combination product under development that is used for the treatment of airflow obstruction in patients with COPD.
- Trial name
- NCT01879410
- Testing
- UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS
- Where
- 72 sites in United States, Chile and 5 more
- Volunteers
- 700 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COPD is a progressive disease characterized by increasing obstruction to airflow and the progressive development of respiratory symptoms including chronic cough, increased sputum production, dyspnea and wheezing.
- Trial name
- NCT03474081
- Testing
- FF/UMEC/VI, Tiotropium, Albuterol/salbutamol
- Where
- 72 sites in United States, Poland and 1 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension
Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
This Phase 2 study was to determine the incidence of increased serum aminotransferase concentrations (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]), as well as the overall safety and tolerability of…
- Trial name
- NCT00423592
- Testing
- ambrisentan
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity.
- Trial name
- NCT02253394
- Testing
- Ambrisentan plus Spironolactone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brigham and Women's Hospital
Lung Neoplasms, Lung Cancer
Feasibility Study Incorporating Lung Function Imaging Into Radiation Therapy for Lung Cancer Patients
The proposed study is in the field of thoracic radiation oncology where radiation therapy is used to treat lung cancer. The primary objective of the early phase clinical trial will be to evaluate the safety of performing…
- Trial name
- NCT02528942
- Testing
- Radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- University of Colorado, Denver
Pulmonary Function; Newborn, Abnormal, Infant Wheeze
Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function
Vitamin C supplementation (500 mg per day) given to pregnant women who can not quit smoking will improve the pulmonary function tests in their offspring measured at 3 months of age.
- Conditions
- Pulmonary Function; Newborn, Abnormal, Infant Wheeze, In-utero Nicotine, Second Hand Smoke
- Trial name
- VCSIP (NCT01723696)
- Testing
- Vitamin C +prenatal vitamin
- Where
- 2 sites in United States
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Asthma
A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with…
- Trial name
- SOLANA (NCT02869438)
- Testing
- Benralizumab
- Where
- 54 sites in United States, Chile and 4 more
- Volunteers
- 233 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult participants with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
- Trial name
- FRONTIER-4 (NCT04631016)
- Testing
- Tozorakimab
- Where
- 90 sites in United States, Australia and 13 more
- Volunteers
- 137 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
NVA237 Versus Placebo 12-week Efficacy Study
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe.
- Trial name
- NCT01709864
- Testing
- NVA237
- Where
- 54 sites in United States
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of single doses of three different dry powder inhalation formulations of AZD3199 administered via Single Inhalation Device (SID) compared to…
- Trial name
- NCT01348139
- Testing
- AZD3199
- Where
- 3 sites in Sweden
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
The primary aim of this study is to quantify and compare changes in lung volumes (as measured by functional residual capacity) in premature infants stable on continuous positive airway pressure (CPAP), and then randomized to two…
- Trial name
- NCT02249143
- Testing
- CPAP and room air
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Oregon Health and Science University
Pulmonary Disease, Chronic Obstructive
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
The purpose of this study is to evaluate the lung function response to UMEC/VI, UMEC, and VI in individual patients using a cross-over design. This is a multicenter, randomized, double-blind, 3-way crossover study.
- Trial name
- NCT01716520
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Umeclidinium 62.5 mcg, Vilanterol 25 mcg
- Where
- 21 sites in Estonia, Germany
- Volunteers
- 182 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary purpose of this study is to evaluate lung function and health related quality of life (HRQoL) after 84 days of treatment with a single inhaler triple therapy combination of FF/UMEC /VI [100/62.5/25 microgram (mcg)]…
- Trial name
- NCT03478696
- Testing
- budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI
- Where
- 57 sites in United States, Czechia and 1 more
- Volunteers
- 732 people
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), or "Lou Gehrig's Disease", is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing…
- Trial name
- NCT00537446
- Testing
- noninvasive positive pressure ventilation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Chronic Obstructive Pulmonary Disease
QVA Mechanistic Efficacy Study (Receptor Effects, Etc)
The purpose of this study was to assess global ventilated lung volume in moderate to severe COPD patients using MRI lung imaging after treatment with QVA149 compared to placebo.
- Trial name
- NCT02634983
- Testing
- QVA149
- Where
- 3 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus
Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and the GLP-1 receptor has been found in…
- Trial name
- NCT02889510
- Testing
- liraglutide
- Where
- 6 sites in Spain
- Volunteers
- 76 people
- Sponsor
- Lecube, Albert, M.D.